该研究证实，IL17REL编码一种诱饵受体，能够结合白细胞介素-17（IL-17）家族细胞因子并抑制肠道炎症。相比之下，由IBD相关IL17REL变异编码的蛋白质则缺乏此功能。作者还发现，转化生长因子β1（TGFβ1）可诱导IL17REL转录，且其表 ...

IBD的患者人群庞大，且存在未满足的治疗需求，2024年药物销售规模约240亿美金。现有治疗药物中，乌帕替尼综合疗效最优，但存在安全性问题。在研药物中，TL1A、TYK2、PDE4等引领研发方向。中国创新药公司有望深度参与IBD大赛道。 IBD的患者人群庞大，且存在未满足的治疗需求，2024年药物销售规模约240亿美金 炎症性肠病（IBD，含溃疡性结肠炎UC/克罗恩病CD）对生活质量影响显著。全球 ...

Switching to a second TNF inhibitor in inflammatory bowel disease may raise the risk for immune-mediated inflammatory ...

黄蜀葵花作为我国传统中药，早在古代就被用于治疗炎症和溃疡，现代研究也证实其具有抗氧化、抗炎功效。但它究竟如何调节肠道菌群以缓解 IBD，一直是未解之谜。 这项研究通过动物实验（DSS 诱导急性结肠炎模型、Il-10 基因敲除小鼠、MUC2 ...

Biologics remain viable options with varying persistence over 1 year in patients with inflammatory bowel disease.

ORLANDO -- Major cardiovascular event risk in patients with inflammatory bowel disease (IBD) was no greater with Janus kinase (JAK) inhibitors than with tumor necrosis factor (TNF) inhibitors, ...

Upadacitinib (UPA; Rinvoq) is an oral selective inhibitor for Janus kinase 1 approved for the treatment of tumor necrosis factor (TNF)-alpha-experienced patients with inflammatory bowel disease (IBD).

Please provide your email address to receive an email when new articles are posted on . Major adverse cardiovascular events occurred among 1.7% of patients on JAK inhibitors vs. 1.9% on anti-TNF ...

Inflammation is the body’s defence system, a way of responding to injury or infection. One key molecule involved in the ...

The AS and IBD Link Can AS Cause IBD? Treatments Lifestyle Remedies When to See a Doctor Ankylosing spondylitis (AS) is a chronic form of inflammatory arthritis that causes pain and stiffness in the ...